Funds holding DAMORA THERAPEUTICS INC
ISIN US36322Q2066 · United States
- Fund holders
- 28
- Of which ETFs
- 3 25 other funds
- Value held
- 193.6M $
- Share of capital
- 11.3 % of 61.7M shares on Aug 7, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 1,758,674 | 52M $ | 0.06 % | 2.85 % | as of Feb 28, 2026 ↗ |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 834,040 | 21.4M $ | 0.25 % | 1.35 % | as of Apr 30, 2026 ↗ |
| Fidelity Growth Company K6 Fund Fidelity Mt. Vernon Street Trust | 521,922 | 15.4M $ | 0.07 % | 0.85 % | as of Feb 28, 2026 ↗ |
| Select Health Care Portfolio Fidelity Select Portfolios | 500,000 | 14.8M $ | 0.24 % | 0.81 % | as of Feb 28, 2026 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 454,559 | 13.4M $ | 0.25 % | 0.74 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Growth Company Fund Fidelity Mt. Vernon Street Trust | 434,739 | 12.9M $ | 0.06 % | 0.70 % | as of Feb 28, 2026 ↗ |
| Fidelity Small Cap Growth K6 Fund Fidelity Securities Fund | 410,184 | 10.5M $ | 0.25 % | 0.66 % | as of Apr 30, 2026 ↗ |
| Fidelity Stock Selector Small Cap Fund Fidelity Capital Trust | 403,200 | 10.3M $ | 0.15 % | 0.65 % | as of Apr 30, 2026 ↗ |
| Fidelity Series Small Cap Opportunities Fund Fidelity Securities Fund | 308,400 | 7.9M $ | 0.16 % | 0.50 % | as of Apr 30, 2026 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 298,142 | 7.7M $ | 0.40 % | 0.48 % | as of Apr 30, 2026 ↗ |
| Fidelity Advisor Health Care Fund Fidelity Advisor Series VII | 280,000 | 7.2M $ | 0.25 % | 0.45 % | as of Apr 30, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 201,735 | 5.2M $ | 0.01 % | 0.33 % | as of Mar 31, 2026 ↗ |
| VIP Health Care Portfolio Variable Insurance Products Fund IV | 118,000 | 3.1M $ | 0.30 % | 0.19 % | as of Mar 31, 2026 ↗ |
| VIP Contrafund Portfolio Variable Insurance Products Fund II | 105,500 | 2.7M $ | 0.01 % | 0.17 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 93,797 | 2.4M $ | 0.03 % | 0.15 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 82,575 | 2.4M $ | 0.01 % | 0.13 % | as of Feb 28, 2026 ↗ |
| Fidelity Fundamental Small-Mid Cap ETF Fidelity Covington Trust | 36,352 | 932.8K $ | 0.07 % | 0.06 % | as of Apr 30, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 29,516 | 873.1K $ | 0.00 % | 0.05 % | as of Feb 28, 2026 ↗ |
| Fidelity Advisor New Insights Fund Fidelity Contrafund | 23,800 | 616.4K $ | 0.00 % | 0.04 % | as of Mar 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 23,248 | 687.7K $ | 0.00 % | 0.04 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Opportunistic Insights Fund Fidelity Contrafund | 12,800 | 331.5K $ | 0.00 % | 0.02 % | as of Mar 31, 2026 ↗ |
| Schwab Total Stock Market Index Fund SCHWAB CAPITAL TRUST | 12,500 | 320.8K $ | 0.00 % | 0.02 % | as of Apr 30, 2026 ↗ |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 5,472 | 140.4K $ | 0.03 % | 0.01 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Extended Equity Market Index Fund T. ROWE PRICE INDEX TRUST, INC. | 4,323 | 112K $ | 0.01 % | 0.01 % | as of Mar 31, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 1,693 | 43.4K $ | 0.02 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Hypatia Women CEO ETF Two Roads Shared Trust | 639 | 16.4K $ | 0.19 % | 0.00 % | as of Apr 30, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 522 | 13.5K $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 167 | 4.3K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 0.40 % | as of Apr 30, 2026 ↗ |
| VIP Health Care Portfolio Variable Insurance Products Fund IV | 0.30 % | as of Mar 31, 2026 ↗ |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 0.25 % | as of Apr 30, 2026 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 0.25 % | as of Feb 28, 2026 ↗ |
| Fidelity Advisor Health Care Fund Fidelity Advisor Series VII | 0.25 % | as of Apr 30, 2026 ↗ |
| Fidelity Small Cap Growth K6 Fund Fidelity Securities Fund | 0.25 % | as of Apr 30, 2026 ↗ |
| Select Health Care Portfolio Fidelity Select Portfolios | 0.24 % | as of Feb 28, 2026 ↗ |
| Hypatia Women CEO ETF Two Roads Shared Trust | 0.19 % | as of Apr 30, 2026 ↗ |
| Fidelity Series Small Cap Opportunities Fund Fidelity Securities Fund | 0.16 % | as of Apr 30, 2026 ↗ |
| Fidelity Stock Selector Small Cap Fund Fidelity Capital Trust | 0.15 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 28 | +20 | 6,956,499 | +2,544.7 % |
| 2026Q1 | 8 | +4 | 263,033 | +1,638.3 % |
| 2025Q4 | 4 | 0 | 15,132 | -22.0 % |
| 2025Q3 | 4 | -2 | 19,395 | +14.7 % |
| 2025Q2 | 6 | +1 | 16,910 | -0.4 % |
| 2025Q1 | 5 | 0 | 16,974 | +1.7 % |
| 2024Q4 | 5 | 16,693 |
Institutional managers
61 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FMR LLC | 9,045,481 | 234.3M $ | as of Mar 31, 2026 |
| Fairmount Funds Management LLC | 8,713,000 | 225.7M $ | as of Mar 31, 2026 |
| Avoro Capital Advisors LLC | 3,783,000 | 98M $ | as of Mar 31, 2026 |
| Venrock Adviser, LLC | 3,603,595 | 93.3M $ | as of Mar 31, 2026 |
| FCPM III SERVICES B.V. | 2,441,000 | 63.2M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 2,399,310 | 62.1M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 2,362,696 | 61.4M $ | as of Mar 31, 2026 |
| VIKING GLOBAL INVESTORS LP | 2,311,082 | 59.9M $ | as of Mar 31, 2026 |
| Bellevue Group AG | 2,298,000 | 59.5M $ | as of Mar 31, 2026 |
| Remedium Capital Partners, LLC | 2,045,473 | 53M $ | as of Mar 31, 2026 |
| Commodore Capital LP | 1,939,000 | 50.2M $ | as of Mar 31, 2026 |
| Cormorant Asset Management, LP | 1,525,000 | 39.5M $ | as of Mar 31, 2026 |
| Balyasny Asset Management L.P. | 1,448,000 | 37.5M $ | as of Mar 31, 2026 |
| a16z Capital Management, L.L.C. | 1,236,157 | 32M $ | as of Mar 31, 2026 |
| PERCEPTIVE ADVISORS LLC | 1,223,000 | 31.7M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 1,193,708 | 30.9M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 1,058,000 | 27.4M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 900,000 | 23.3M $ | as of Mar 31, 2026 |
| BRAIDWELL LP | 894,846 | 23.2M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 600,000 | 15.5M $ | as of Mar 31, 2026 |
| Blackstone Inc. | 503,522 | 13M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 471,646 | 12.2M $ | as of Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 450,000 | 11.7M $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 335,710 | 8.7M $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 282,436 | 7.3M $ | as of Mar 31, 2026 |
Declared shareholders of DAMORA THERAPEUTICS INC
There are 5 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Avoro Capital Advisors LLC and 1 other | 6.27 % | 3,783,000 | as of Mar 31, 2026 · SCHEDULE 13G |
| Paragon Therapeutics, Inc. | 3.39 % | 2,045,473 | as of Feb 9, 2026 · SCHEDULE 13G |
| Paramora Holding LLC | 3.39 % | 2,045,473 | as of Feb 9, 2026 · SCHEDULE 13G |
| Point72 Asset Management, L.P. and 2 others | 2.00 % | 1,193,708 | as of Mar 31, 2026 · SCHEDULE 13G |
| Jain Global LLC and 2 others | 0.00 % | 0 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding DAMORA THERAPEUTICS INC". https://titelia.com/en/stocks/damora-therapeutics-inc-US36322Q2066